Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for reducing proteinuria in type 2 diabetic nephropathy
IRCT2017080210222N10Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of pioglitazone in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM), sponsored by Shahrekord University of Medical Sciences. Primary endpoint: Change in proteinuria. Started Sep 2017; status: completed.
02
Drugs
pioglitazone
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT2017080210222N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017080210222N10.